Journal of Clinical Oncology, Vol 15, 2945-2953, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years

Y Bastion, JY Blay, M Divine, P Brice, D Bordessoule, C Sebban, M Blanc, H Tilly, P Lederlin, E Deconinck, B Salles, C Dumontet, J Briere and B Coiffier
Service d'Hematologie, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.

PURPOSE: To clarify disease characteristics and optimal treatment for elderly patients with non-Hodgkin's lymphoma (NHL), we performed a randomized trial in 453 patients older than 69 years with aggressive lymphoma. PATIENTS AND METHODS: Two hundred twenty patients received cyclophosphamide 750 mg/m2, teniposide (VM-26) 75 mg/m2, and prednisone 40 mg/m2/d for 5 days (CVP) and 233 patients received CVP plus pirarubicin (THP-doxorubicin) 50 mg/m2 (CTVP), each for six courses every 3 weeks. RESULTS: The median age was 75 years. Most patients had clinically aggressive disease; 30% had one and 53% two or three adverse prognostic parameters as defined by the International Prognostic Index. More patients on the CTVP arm had an elevated lactic dehydrogenase (LDH) level, but the two groups were otherwise well balanced. CTVP treatment was more frequently associated with leukopenia, thrombocytopenia, and infectious complications. Death during chemotherapy occurred in 16% and 21% of patients on the CVP and CTVP arms, respectively (not significant). Forty percent of patients achieved a complete response (CR): 47% on CTVP and 32% on CVP (chi2 = 20.98, P = .0001). The median time to treatment failure (TTF) was 7 months for CTVP versus 5 months for CVP (log-rank test, P < .05). The median survival time was 13 months in both groups; however, the 5-year survival rate was 26% with CTVP versus 19% with CVP (chi2 = 4.68, P < .05). Lymphoma progression was the primary cause of death. CONCLUSION: Elderly patients with aggressive lymphoma have an aggressive disease with adverse prognostic parameters at the time of diagnosis. Slightly longer survival was observed for patients treated with an anthracycline- containing regimen.

This article has been cited by other articles:

				N. Mourad, N. Mounier, J. Briere, E. Raffoux, A. Delmer, A. Feller, C. J. L. M. Meijer, J.-F. Emile, R. Bouabdallah, A. Bosly, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, May 1, 2008; 111(9): 4463 - 4470. [Abstract] [Full Text] [PDF]

				C. Thieblemont, A. Grossoeuvre, R. Houot, F. Broussais-Guillaumont, G. Salles, C. Traulle, D. Espinouse, and B. Coiffier Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome Ann. Onc., April 1, 2008; 19(4): 774 - 779. [Abstract] [Full Text] [PDF]

				C. Thieblemont and B. Coiffier Lymphoma in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1916 - 1923. [Abstract] [Full Text] [PDF]

				C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood, March 1, 2007; 109(5): 2183 - 2189. [Abstract] [Full Text] [PDF]

				J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study Blood, December 15, 2006; 108(13): 4163 - 4169. [Abstract] [Full Text] [PDF]

				S. Monfardini, S. M. L. Aversa, V. Zoli, L. Salvagno, A. Bianco, R. Bordonaro, G. Benevolo, M. Crugnola, G. Crivellari, P. Vivaldi, et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas Ann. Onc., August 1, 2005; 16(8): 1352 - 1358. [Abstract] [Full Text] [PDF]

				J.K. Doorduijn, B. van der Holt, G.W. van Imhoff, K.G. van der Hem, M.H.H. Kramer, M.H.J. van Oers, G.J. Ossenkoppele, M.R. Schaafsma, L.F. Verdonck, G.E.G. Verhoef, et al. CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., August 15, 2003; 21(16): 3041 - 3050. [Abstract] [Full Text] [PDF]

				E. Osby, H. Hagberg, S. Kvaloy, L. Teerenhovi, H. Anderson, E. Cavallin-Stahl, H. Holte, J. Myhre, H. Pertovaara, and M. Bjorkholm CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial Blood, May 15, 2003; 101(10): 3840 - 3848. [Abstract] [Full Text] [PDF]

				E. M. Bessell, A. Burton, A. P. Haynes, J. Glaholm, J. A. Child, M. H. Cullen, J. M. Davies, G. M. Smith, I. O. Ellis, A. Jack, et al. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma Ann. Onc., February 1, 2003; 14(2): 258 - 267. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, F. Gherlinzoni, S. Storti, A. Zaccaria, E. Pavone, L. Moretti, P. Gentilini, L. Guardigni, A. De Renzo, P. P. Fattori, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients Ann. Onc., September 1, 2002; 13(9): 1364 - 1369. [Abstract] [Full Text] [PDF]

				B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma N. Engl. J. Med., January 24, 2002; 346(4): 235 - 242. [Abstract] [Full Text] [PDF]

				C. T. Kouroukis, G. P. Browman, R. Esmail, and R. M. Meyer Chemotherapy for Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive-Histology Non-Hodgkin Lymphoma: A Systematic Review Ann Intern Med, January 15, 2002; 136(2): 144 - 152. [Abstract] [Full Text] [PDF]

				P. N. Mainwaring, D. Cunningham, W. Gregory, P. Hoskin, B. Hancock, A. J. Norton, K. MacLennan, P. Smith, G. V. Hudson, and D. Linch Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO Blood, May 15, 2001; 97(10): 2991 - 2997. [Abstract] [Full Text] [PDF]

				L. Balducci, G. H. Lyman, and H. Ozer Patients Aged {>=} 70 Are at High Risk for Neutropenic Infection and Should Receive Hemopoietic Growth Factors When Treated With Moderately Toxic Chemotherapy J. Clin. Oncol., March 1, 2001; 19(5): 1583 - 1585. [Full Text] [PDF]

				C. Adida, C. Haioun, P. Gaulard, E. Lepage, P. Morel, J. Briere, H. Dombret, F. Reyes, J. Diebold, C. Gisselbrecht, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas Blood, September 1, 2000; 96(5): 1921 - 1925. [Abstract] [Full Text] [PDF]

				L. Balducci and M. Extermann Management of Cancer in the Older Person: A Practical Approach Oncologist, June 1, 2000; 5(3): 224 - 237. [Abstract] [Full Text]

				H. Tilly, N. Mounier, P. Lederlin, J. Briere, B. Dupriez, C. Sebban, A. Bosly, P. Biron, C. Nouvel, R. Herbrecht, et al. Randomized Comparison of ACVBP and m-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study J. Clin. Oncol., March 13, 2000; 18(6): 1309 - 1315. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, S. Storti, A. Zaccaria, L. Moretti, M. Magagnoli, E. Pavone, P. Gentilini, L. Guardigni, M. Gobbi, P. P. Fattori, et al. Elderly Aggressive-Histology Non-Hodgkin's Lymphoma: First-Line VNCOP-B Regimen Experience on 350 Patients Blood, July 1, 1999; 94(1): 33 - 38. [Abstract] [Full Text] [PDF]

				M. B. Moller, A.-M. Gerdes, K. Skjodt, L. S. Mortensen, and N. T. Pedersen Disrupted p53 Function as Predictor of Treatment Failure and Poor Prognosis in B- and T-Cell Non-Hodgkin's Lymphoma Clin. Cancer Res., May 1, 1999; 5(5): 1085 - 1091. [Abstract] [Full Text] [PDF]

				P J Mounter and A L Lennard Classic diseases revisited: Management of non-Hodgkin's lymphomas Postgrad. Med. J., January 1, 1999; 75(879): 2 - 6. [Abstract] [Full Text]

				C. Gisselbrecht, P. Gaulard, E. Lepage, B. Coiffier, J. Briere, C. Haioun, D. Cazals-Hatem, A. Bosly, L. Xerri, H. Tilly, et al. Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas Blood, July 1, 1998; 92(1): 76 - 82. [Abstract] [Full Text] [PDF]